Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/James Condulis
STIF
James Condulis
Stifel Nicolaus
Wall Street Analyst
★★★☆☆
#1144
on 13Foresight · ranked by our own returns
50%
Success Rate
-3.0%
Average Return
4 of 8 calls profitable · -7.3% vs benchmark
📈 Across the calls we could measure, roughly 50% of James Condulis's ratings turned a profit when each position was held for 1 year — averaging -3.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

36 Buy 7 Hold 0 Sell
James's Stock Coverage 9 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
FULC
Fulcrum Therapeutics
 Jun 02, 2026 HOLD Hold
+151.5% avg upside
13 analysts
$3.00
15.70% Downside
 ·
EWTX
Edgewise Therapeutics
 Jun 01, 2026 HOLD Strong Buy
+27.2% avg upside
14 analysts
 — -15.7%
TECX
Tectonic Therapeutic
 May 08, 2026 BUY Strong Buy
+88.0% avg upside
24 analysts
$75.00
150.94% Upside
 -3.8%
MIRM
Mirum Pharmaceuticals
 May 07, 2026 BUY Strong Buy
+10.1% avg upside
21 analysts
$136.00
27.48% Upside
 +4.1%
CYTK
Cytokinetics
 May 06, 2026 BUY Strong Buy
+9.9% avg upside
36 analysts
$108.00
38.63% Upside
 +5.5%
AMLX
Amylyx Pharmaceuticals Inc
 Mar 03, 2026 BUY Strong Buy
+48.4% avg upside
13 analysts
$21.00
35.40% Upside
 +8.9%
AARD
Aardvark Therapeutics, Inc.
 Mar 02, 2026 HOLD Buy
+399.2% avg upside
12 analysts
$6.00
53.06% Upside
 -12.8%
NAMS
NewAmsterdam Pharma Company
 Feb 06, 2026 BUY Strong Buy
+54.8% avg upside
18 analysts
$50.00
65.92% Upside
 -13.0%
XFOR
X4 Pharmaceuticals
 Dec 05, 2025 BUY Strong Buy
+513.8% avg upside
15 analysts
$10.00
139.74% Upside
 +2.5%
🔒 4 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
James Condulis — Frequently Asked Questions
How accurate are James Condulis's stock ratings?
Based on the calls 13Foresight could measure, about 50% of James's ratings were profitable over a one-year hold, with an average return of -3.0% per rating, or -7.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is James ranked on 13Foresight?
James Condulis is currently ranked #1144 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does James cover?
James most recently has ratings on FULC, EWTX, TECX, MIRM, CYTK, AMLX, AARD, NAMS, XFOR. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.